Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 11:06 AM ET
Protagonist Therapeutics Inc (PTGX) Stock Forecast
Analysts expect Protagonist Therapeutics (PTGX) to earn $5.09 per share in the fiscal year ending Dec 31, 2026, on revenue of $566.26M. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.79, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 21.4% |
| Buy | 11 | 78.6% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 90.0% and revenue estimates fall 57.6%.
- Fiscal year ending Dec 31, 2026
- $5.09
- EPS consensus, revenue $566.26M
- Fiscal year ending Dec 31, 2027
- $0.51
- EPS consensus, revenue $240.25M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.09 | $3.04 to $7.30 | 12 | $566.26M | $420.00M to $674.50M | 13 |
| Dec 31, 2027 | $0.51 | -$1.17 to $7.60 | 11 | $240.25M | $116.00M to $797.90M | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.46 for the quarter ending Dec 31, 2026 to $0.36 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.46 | -$0.83 to $0.65 | 16 | $22.64M | $2.65M to $88.63M | 15 |
| Mar 31, 2027 | $0.36 | -$0.35 to $1.85 | 4 | $58.33M | $16.10M to $191.00M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 3 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.2% from $4.75.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.09 | $4.77 | $4.67 | $4.79 | $4.75 | +7.0% |
| Fiscal year ending Dec 31, 2027 | $0.51 | -$0.10 | -$0.20 | -$0.20 | -$0.14 | N/A |
| Quarter ending Mar 31, 2027 | $0.36 | -$0.09 | -$0.13 | -$0.13 | $0.03 | +1323.8% |
Frequently Asked Questions About PTGX
What is the PTGX stock forecast?
Consensus analyst estimates put Protagonist Therapeutics's EPS at $5.09 for the fiscal year ending Dec 31, 2026, on revenue of $566.26M. The consensus rating from 14 analysts is Buy.
How do analysts rate PTGX stock?
Of 14 analysts covering Protagonist Therapeutics, 3 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PTGX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.09, with estimates from $3.04 to $7.30 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.51, with estimates from -$1.17 to $7.60 from 11 analysts.
What revenue do analysts expect from Protagonist Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $566.26M, with estimates from $420.00M to $674.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $240.25M, with estimates from $116.00M to $797.90M.
How many analysts cover PTGX?
14 analysts rate Protagonist Therapeutics stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PTGX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors